Abstract：
BACKGROUND: After mild traumatic brain injury (mTBI), some patients experience symptoms that persist for weeks to months. Recovery from mTBI is primarily assessed using selfreported symptom questionnaires. Blood biomarkers, including microRNA species, have shown promise to assist diagnosis of mTBI, however, little is known about how blood microRNA measures might predict symptom recovery.
OBJECTIVE: The aim of this study was to investigate the variances in plasma microRNAs on the day of injury between individuals with mTBI who report post-concussive symptoms at the 28- day mark and those who do not.
METHODS: Patients who presented to an adult, tertiary referral hospital emergency department on the day of the injury and were diagnosed with isolated mTBI (n=35) were followed up for 28 days. Venous blood samples were collected and symptom severity was assessed using the Rivermead Post-Concussion Symptom Questionnaire (RPQ) on the day of injury and at 28 days. Patients who reported ongoing symptoms of total RPQ score ≥10 or at least one symptom severity ≥2, were compared to those with lesser symptom severity or symptom resolution.
RESULTS: There were 9 (25.7%; 95%CI: 12.5-43.3) patients who reported persistent symptoms. Day of injury plasma miR-223-3p levels were significantly higher in individuals with ongoing symptoms compared to those without, however, no such differences were observed for miRs 142- 3p, 423-3p, 32-5p, 144-3p, and let-7f-5p.
CONCLUSIONS: Acute plasma miR-223-3p levels appear to detect patients who later have persistent symptoms after mTBI. The results demonstrate the potential utility for such biomarkers to assist in decisions towards early referral for therapy after mTBI.
OBJECTIVE: The aim of this study was to investigate the variances in plasma microRNAs on the day of injury between individuals with mTBI who report post-concussive symptoms at the 28- day mark and those who do not.
METHODS: Patients who presented to an adult, tertiary referral hospital emergency department on the day of the injury and were diagnosed with isolated mTBI (n=35) were followed up for 28 days. Venous blood samples were collected and symptom severity was assessed using the Rivermead Post-Concussion Symptom Questionnaire (RPQ) on the day of injury and at 28 days. Patients who reported ongoing symptoms of total RPQ score ≥10 or at least one symptom severity ≥2, were compared to those with lesser symptom severity or symptom resolution.
RESULTS: There were 9 (25.7%; 95%CI: 12.5-43.3) patients who reported persistent symptoms. Day of injury plasma miR-223-3p levels were significantly higher in individuals with ongoing symptoms compared to those without, however, no such differences were observed for miRs 142- 3p, 423-3p, 32-5p, 144-3p, and let-7f-5p.
CONCLUSIONS: Acute plasma miR-223-3p levels appear to detect patients who later have persistent symptoms after mTBI. The results demonstrate the potential utility for such biomarkers to assist in decisions towards early referral for therapy after mTBI.
摘要：
背景：轻度创伤性脑损伤（mTBI）后，一些患者会出现持续数周至数月的症状。mTBI的恢复主要使用自我报告症状问卷进行评估。血液生物标志物,包括microRNA种类,有希望帮助诊断mTBI，然而,关于血液microRNA测量如何预测症状恢复知之甚少。
目的：本研究的目的是研究在28天时报告脑震荡后症状的mTBI患者和未报告的mTBI患者在损伤当天血浆microRNAs的变化。
方法：向成人就诊的患者，三级转诊医院急诊科在受伤当天并被诊断为孤立性mTBI(n=35)随访28天。在受伤当天和第28天，收集静脉血样品，并使用Rivermead脑震荡后症状问卷（RPQ）评估症状严重程度。将报告总RPQ评分≥10或至少一种症状严重程度≥2的持续症状的患者与症状严重程度或症状缓解程度较低的患者进行比较。
结果：有9例（25.7%；95CI：12.5-43.3）患者报告持续症状。损伤日血浆miR-223-3p水平在有持续症状的个体中显著高于无，然而,对于miR142-3p没有观察到这样的差异，423-3p，32-5p，144-3p，还有let-7f-5p.
结论：急性血浆miR-223-3p水平似乎可以检测到mTBI后有持续症状的患者。结果证明了此类生物标志物有助于决定mTBI后早期转诊治疗的潜在效用。
目的：本研究的目的是研究在28天时报告脑震荡后症状的mTBI患者和未报告的mTBI患者在损伤当天血浆microRNAs的变化。
方法：向成人就诊的患者，三级转诊医院急诊科在受伤当天并被诊断为孤立性mTBI(n=35)随访28天。在受伤当天和第28天，收集静脉血样品，并使用Rivermead脑震荡后症状问卷（RPQ）评估症状严重程度。将报告总RPQ评分≥10或至少一种症状严重程度≥2的持续症状的患者与症状严重程度或症状缓解程度较低的患者进行比较。
结果：有9例（25.7%；95CI：12.5-43.3）患者报告持续症状。损伤日血浆miR-223-3p水平在有持续症状的个体中显著高于无，然而,对于miR142-3p没有观察到这样的差异，423-3p，32-5p，144-3p，还有let-7f-5p.
结论：急性血浆miR-223-3p水平似乎可以检测到mTBI后有持续症状的患者。结果证明了此类生物标志物有助于决定mTBI后早期转诊治疗的潜在效用。
